A Phase 2 Multi Cohort Open Label Multi Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48 ADC) Alone and in Combination with Pembrolizumab in Subjects with Locally Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2

Go Back to All Clinical Trials

A Phase 2 Multi Cohort Open Label Multi Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48 ADC) Alone and in Combination with Pembrolizumab in Subjects with Locally Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies

A Phase 2 Multi Cohort Open Label Multi Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48 ADC) Alone and in Combination with Pembrolizumab in Subjects with Locally Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2

Recruitment Status

Contact the research team to learn more about this study.

Recruitment Status